Patents by Inventor Andrew Peter Cridland

Andrew Peter Cridland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINASE INHIBITORS
    Publication number: 20140364412
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Kinase inhibitors
    Patent number: 8907094
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 9, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • KINASE INHIBITORS
    Publication number: 20140343055
    Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 20, 2014
    Applicant: Chiesi Farmaceutici S.p.A
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
  • KINASE INHIBITORS
    Publication number: 20140323470
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: July 14, 2014
    Publication date: October 30, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 8835431
    Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: September 16, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
  • Piperazine derivatives for blocking Ca2.2 calcium channels
    Patent number: 8697703
    Abstract: The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 15, 2014
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Jag Paul Heer, Andrew Peter Cridland, David Norton
  • Piperazine derivatives used as CAV2.2 calcium channel modulators
    Patent number: 8530478
    Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: September 10, 2013
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Peter Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
    Publication number: 20130072499
    Abstract: The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.
    Type: Application
    Filed: January 14, 2011
    Publication date: March 21, 2013
    Inventors: Jag Paul Heer, Andrew Peter Cridland, David Norton
  • PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS
    Publication number: 20110130379
    Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 15, 2009
    Publication date: June 2, 2011
    Applicant: CONVERGENCE PHARMACEUTICALS LIMITED
    Inventors: Paul John Beswick, Alister Campbell, Andrew Peter Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile